- BMB-101 demonstrated a complete elimination of drop attacks in the DBA/2 mouse model - - The DBA/2 model is highly predictive of sudden unexpected death in epilepsy (SUDEP) - - Findings highlight BMB-101’s potential to address critical gaps in SUDEP prevention - NEW YORK and VANCOUVER, British Columbia, May 13, 2025 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) (“Bright Minds” or the “Company”), a company focused on developing highly selective 5-HT2 agonists for the treatmen ...

Warwick, NY, May 13, 2025 (GLOBE NEWSWIRE) -- Ozop Energy Solutions, Inc. (OTC: OZSC) ("Ozop" or the "Company"), a Company focused in the renewable energy sector, today provided an update to its shareholders on recent strategic milestones and upcoming initiatives. With a diverse portfolio of innovative energy solutions, Ozop remains focused on capturing a share of the rapidly growing renewable energy market. Ozop’s wholly owned subsidiary, Automated Room Controls, Inc. (DBA ARC), has made substantial progre ...

Newly allowed patent extends Wearable Devices’ innovative gesture technology into the domain of voice control YOKNEAM ILLIT, ISRAEL, May 13, 2025 (GLOBE NEWSWIRE) -- Wearable Devices Ltd. (the “Company” or “Wearable Devices”) (Nasdaq: WLDS, WLDSW), a technology growth company specializing in artificial intelligence (“AI")-powered touchless sensing wearables, today announced that the United States Patent and Trademark Office has allowed its patent titled “Gesture and Voice-Controlled Interface Device.” This ...

Optical Engine Manufacturing Operational at Globetronics in Malaysia and POET Technologies Snd. Bhd. Established as Wholly Owned SubsidiaryTORONTO, May 13, 2025 (GLOBE NEWSWIRE) -- POET Technologies Inc. ("POET" or the "Company") (TSX Venture: PTK; NASDAQ: POET), a leader in the design and implementation of highly-integrated optical engines and light sources for artificial intelligence networks, today announced the appointment of Ghazi M. Chaoui, PhD, MBA as its Senior Vice President of Global Manufacturing ...

Management Delivers Impressive 80% Revenue Growth Quarter-Over-Quarter Beats All Revenue and EPS Estimates By A Wide Margin Q1 2025 Revenue Exceeds Entire 2024 Annual Revenue Closed $8.5 Million Acquisition Of AI Social Commerce Technology Platform Lyvecom $5 Million Cash Added To Balance Sheet In Non-Dilutive, Non-Convertible, Preferred Stock Deal Zero Debt - Strong Cash Position – Expected To Fund Operations Into 2028 And Beyond Increased Growth Projected For Q2 2025 LAS VEGAS, May 13, 2025 (GLOBE NEWSWIR ...

Survival observations in mTNBC patients correlated with increased PD-L1 expression Preliminary evidence suggests leronlimab has potential to turn “cold” tumors “hot” VANCOUVER, Washington, May 13, 2025 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, today announced new data suggesting a novel mechanism of action of leronlimab for the treatment of solid tumors ...

Addresses key challenges for CAR-T therapies Potential to significantly reduce costs and improve clinical efficacy of engineered effector T cells Data Shared at 2025 Annual Meeting of American Association of Immunologists MIRAMAR, Fla., May 13, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (“HCWB” or the “Company”) (NASDAQ: HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies to extend healthspan by targeting the link between chronic inf ...

OLD GREENWICH, Conn., May 13, 2025 (GLOBE NEWSWIRE) -- Hudson Global, Inc. (Nasdaq: HSON) ("Hudson Global" or "the Company"), a leading global total talent solutions company, announced today financial results for the first quarter ended March 31, 2025. 2025 First Quarter Summary Revenue of $31.9 million decreased 6.0% from the first quarter of 2024 and 3.3% in constant currency.Adjusted net revenue of $16.4 million increased 0.4% from the first quarter of 2024 and 2.2% in constant currency.Net loss was $1.8 ...

20% sequential quarterly revenue growth and 91% year-over-year quarterly gross profit growth Continued momentum from recurring higher-margin cartridge sales now reaching 58% of total sales for the nine months ended March 31, 2025 35 new accounts and international growth during Q3 bring total active accounts to over 450 NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive t ...

SARASOTA, Fla., May 13, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a biotechnology company focused on developing novel intranasal therapies for brain-related disorders, today announced that it has received approval from the Human Research Ethics Committee (HREC) in Australia to initiate its Phase II clinical trial evaluating ONP-002, the Company's proprietary neuroprotective therapy, for the treatment of mild traumatic brain injury (mTBI), aka concussion. This approval marks a significa ...